Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-201 in Moderate-to-Severe Atopic Dermatitis (Phase II)
CTR20211538Phase 2Completed
- Sponsor
- Connect Biopharma
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rademikibart in atopic dermatitis (AD), sponsored by Connect Biopharma. Started Jul 2021; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20211538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211538.